CACI International (CACI)’s director William Wallace Sold 90 shares of the Company; Charming Shoppes Has 1.07 Sentiment

February 15, 2018 - By Marie Mckinney

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $569.98 million. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Caci International Inc director William Wallace on the February 15, 2018 unloaded a total of 90 shares of the Pinksheet-listed Caci International Inc worth $13,626 USD. This is based on an average share price of $151.4 USD. This important trade was filled on February 15, 2018 and is free at your disposal for review on the Washington-based Security and Exchange Commission’s website. William Wallace now possess 9,575 shares of the Firm.

Investors sentiment decreased to 0.93 in Q3 2017. Its down 0.46, from 1.39 in 2017Q2. It turned negative, as 15 investors sold CACI International Inc shares while 85 reduced holdings. 18 funds opened positions while 75 raised stakes. 21.57 million shares or 0.21% less from 21.61 million shares in 2017Q2 were reported. Wellington Group Incorporated Limited Liability Partnership reported 0.01% of its portfolio in CACI International Inc (NYSE:CACI). Ww Asset Mgmt Incorporated holds 0.01% or 1,803 shares in its portfolio. Adage Partners Group Limited Liability Com has 0.02% invested in CACI International Inc (NYSE:CACI) for 55,403 shares. First Retail Bank Of Omaha owns 0.09% invested in CACI International Inc (NYSE:CACI) for 11,060 shares. State Street accumulated 597,878 shares. The California-based California State Teachers Retirement Systems has invested 0.01% in CACI International Inc (NYSE:CACI). Nationwide Fund Advsrs has 54,954 shares. Fmr Lc owns 1.40 million shares. Zacks Inv Management reported 0.04% in CACI International Inc (NYSE:CACI). Regentatlantic Capital Limited Co holds 0.02% or 1,816 shares in its portfolio. The Ontario – Canada-based Manufacturers Life Insurance The has invested 0% in CACI International Inc (NYSE:CACI). Sector Pension Investment Board has 0.01% invested in CACI International Inc (NYSE:CACI) for 15,478 shares. Employees Retirement Systems Of Texas has invested 0.03% in CACI International Inc (NYSE:CACI). Commercial Bank Of America De invested in 182,561 shares. Ahl Ptnrs Limited Liability Partnership has 0.18% invested in CACI International Inc (NYSE:CACI).

The stock decreased 1.06% or $1.6 during the last trading session, reaching $149.15. About 24,655 shares traded. CACI International Inc (NYSE:CACI) has risen 32.11% since February 15, 2017 and is uptrending. It has outperformed by 15.41% the S&P500.

CACI International Inc, together with its subsidiaries, provides information solutions and services in North America and internationally. The company has market cap of $3.67 billion. The firm offers business systems solutions in the areas of financial, human capital, asset and materials, and administrative management; develops, integrates, and operates command and control solutions; and develops and integrates solutions that deliver multi-level unified communications from the enterprise directly to and from the tactical edge. It has a 13.93 P/E ratio. It also provides cyber security solutions, as well as supports cyber activities of federal clients and the intelligence community.

Among 17 analysts covering Caci International Inc (NYSE:CACI), 12 have Buy rating, 0 Sell and 5 Hold. Therefore 71% are positive. Caci International Inc has $174.0 highest and $91 lowest target. $148.14’s average target is -0.68% below currents $149.15 stock price. Caci International Inc had 61 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of CACI International Inc (NYSE:CACI) earned “Buy” rating by Noble Financial on Friday, June 23. The company was maintained on Thursday, October 29 by Maxim Group. The firm has “Buy” rating given on Monday, June 19 by Cowen & Co. As per Wednesday, December 9, the company rating was maintained by Stifel Nicolaus. The rating was upgraded by Cowen & Co on Monday, June 12 to “Outperform”. Stifel Nicolaus maintained the shares of CACI in report on Thursday, June 23 with “Buy” rating. As per Friday, February 5, the company rating was upgraded by Citigroup. RBC Capital Markets maintained the shares of CACI in report on Friday, June 24 with “Sector Perform” rating. The rating was upgraded by Jefferies to “Buy” on Monday, July 17. The firm has “Hold” rating given on Friday, January 12 by Credit Suisse.

Since August 14, 2017, it had 0 buys, and 6 selling transactions for $3.33 million activity. PHILLIPS WARREN R had sold 400 shares worth $50,120 on Thursday, August 24. LONDON J PHILLIP sold $1.62M worth of CACI International Inc (NYSE:CACI) on Thursday, February 1. $711,450 worth of CACI International Inc (NYSE:CACI) shares were sold by MUTRYN THOMAS A. $50,100 worth of stock was sold by Johnson Gregory G on Monday, August 28. 750 shares were sold by REVOILE CHARLES P, worth $95,460. Shares for $11,575 were sold by Wallace William S.

Ratings analysis reveals 100% of Coherus BioSciences’s analysts are positive. Out of 2 Wall Street analysts rating Coherus BioSciences, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $40.0 while the high is $43.0. The stock’s average target of $41.50 is 335.70% above today’s ($9.525) share price. CHRS was included in 2 notes of analysts from September 7, 2016. As per Wednesday, September 7, the company rating was initiated by Maxim Group. The stock of Coherus Biosciences, Inc. (NASDAQ:CHRS) has “Outperform” rating given on Wednesday, October 19 by Robert W. Baird.

Temasek Holdings (Private) Ltd holds 0.51% of its portfolio in Coherus Biosciences, Inc. for 6.56 million shares. Kohlberg Kravis Roberts & Co. L.P. owns 3.06 million shares or 0.47% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.39% invested in the company for 638,400 shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 0.31% in the stock. Highland Capital Management Lp, a Texas-based fund reported 433,930 shares.

Analysts await Coherus Biosciences, Inc. (NASDAQ:CHRS) to report earnings on March, 12. They expect $-0.90 earnings per share, up 47.37% or $0.81 from last year’s $-1.71 per share. After $-1.09 actual earnings per share reported by Coherus Biosciences, Inc. for the previous quarter, Wall Street now forecasts -17.43% EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: